A Single Ascending Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1092 in Healthy Subjects and in Subjects With Type 1 Diabetes Mellitus
Phase of Trial: Phase I
Latest Information Update: 16 Oct 2017
At a glance
- Drugs Insulin lispro (Primary) ; MK-1092 (Primary) ; Insulin glargine
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Merck Sharp & Dohme
- 11 Oct 2017 Planned End Date changed from 22 Jun 2018 to 21 Sep 2018.
- 11 Oct 2017 Planned primary completion date changed from 22 Jun 2018 to 21 Sep 2018.
- 02 Aug 2017 Status changed from not yet recruiting to recruiting.